ArticleJournal of palliative medicine2014
Patterns of hospice use in patients dying from hematologic malignancies.
Article in Journal of palliative medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Duration of palliative care before death in international routine practice: a systematic review and meta-analysis.BMC medicine · 2020Pooled it
- Effects and satisfaction of dignity therapy among patients with hematologic neoplasms in the Chinese cultural context: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia.Blood · 2018Trial
- Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists.Annals of oncology : official journal of the European Society for Medical Oncology · 2015Trial
- Health-system burden of higher-risk myelodysplastic syndromes in England: a literature-based micro-cost analysis.BMJ open · 2026Article
- Differences in Perspectives and Policies Regarding End-of-Life Care Between Hematologists and Gastroenterologists.Cancer medicine · 2026Article
- Article
- Clinical Features of Patients With Hematological Malignancies Treated at the Palliative Care Unit.Palliative medicine reports · 2023Article
- End-of-Life Care of Acute Myeloid Leukemia Compared with Aggressive lymphoma in Patients Who Are Eligible for Intensive Chemotherapy: An Observational Study in a Japanese Community Hospital.Palliative medicine reports · 2023Article
- Rural-urban disparities in place of death in hematologic malignancies in the United States, 2003 to 2019.Blood advances · 2022Article
- End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma.Journal of palliative medicine · 2022Article
- Article
- Current status of intensive end-of-life care in children with hematologic malignancy: a population-based study.BMC palliative care · 2021Article
- Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Article
- Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved Caregivers.Journal of pain and symptom management · 2020Article
- Article
- Hospice or Hospital: The Costs of Dying of Cancer in the Oncology Care Model.Palliative medicine reports · 2020Article
- Association between palliative care and end-of-Life care for patients with hematological malignancies: A population-based study.Medicine · 2019Observational
- A Three-Step Letter Advance Directive Procedure to Facilitate Patient-Proxy Alignment in Advance Care Planning.Journal of palliative medicine · 2018Article
- Transfusion practices at end of life for hematopoietic stem cell transplant patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundHospice brings substantial clinical benefits to dying patients and families but is underutilized by patients dying of hematologic malignancies (HM); nationwide, only 2% of HM patients use hospice. There are 70,000 deaths among U.S. patients with hematologic malignancies yearly.
objectiveWe measured the use and length of stay (LOS) in hospice among patients with HMs at a large academic cancer center.
designThis was a single center retrospective review of adult patients (≥18 years) with lymphoma, leukemia, myelodysplastic syndrome, aplastic anemia, and multiple myeloma referred for hospice. MEASUREMENTS: Information included demographics, transplant, hospice type, LOS, and use of "expanded access" services.
resultsFifty-nine patients were referred to hospice, and 53 utilized hospice services, 25% of 209 HM decedents. Thirty-five received home hospice and 18 used inpatient hospice. The median home hospice LOS was nine days (SD 13) and inpatient hospice six days (SD 10). Nine patients with "expanded access" hospice received only a few blood transfusions, and none received radiation.
conclusionsHM patients are referred late or never for hospice services. Studies evaluating earlier integration of palliative and hospice care with usual HM care are warranted. We present a one-page negotiation form that we have found useful in negotiations among HM physicians, hospice medical directors, and payers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.